FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 161 filers reported holding FATE THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $784,000 | -36.1% | 31,652 | 0.0% | 0.03% | -27.9% |
| Q1 2022 | $1,227,000 | -71.2% | 31,652 | -56.5% | 0.04% | -68.6% |
| Q4 2021 | $4,255,000 | -1.3% | 72,727 | 0.0% | 0.14% | -1.4% |
| Q3 2021 | $4,311,000 | -31.7% | 72,727 | 0.0% | 0.14% | -32.2% |
| Q2 2021 | $6,312,000 | -49.1% | 72,727 | -51.6% | 0.20% | -51.9% |
| Q1 2021 | $12,396,000 | -18.0% | 150,343 | -9.6% | 0.43% | -19.8% |
| Q4 2020 | $15,123,000 | +74.0% | 166,317 | -23.5% | 0.53% | +62.9% |
| Q3 2020 | $8,692,000 | +36.5% | 217,462 | +17.1% | 0.33% | +34.7% |
| Q2 2020 | $6,370,000 | +73.1% | 185,672 | +12.1% | 0.24% | +45.8% |
| Q1 2020 | $3,680,000 | +13.5% | 165,672 | 0.0% | 0.17% | +35.0% |
| Q4 2019 | $3,242,000 | +26.0% | 165,672 | 0.0% | 0.12% | +9.8% |
| Q3 2019 | $2,573,000 | +419.8% | 165,672 | +579.6% | 0.11% | +460.0% |
| Q2 2019 | $495,000 | – | 24,379 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $46,987,000 | 60.92% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $278,604,000 | 36.08% |
| Darwin Global Management, Ltd. | 1,370,133 | $112,967,000 | 22.12% |
| Redmile Group, LLC | 12,957,222 | $1,068,323,000 | 15.05% |
| Copernicus Capital Management, LLC | 8,000 | $660,000 | 10.66% |
| Casdin Capital, LLC | 3,400,000 | $280,330,000 | 8.35% |
| Grosvenor Holdings, L.L.C. | 1,123,576 | $92,639,000 | 6.81% |
| DAFNA Capital Management LLC | 314,360 | $25,919,000 | 6.15% |
| Ally Bridge Group (NY) LLC | 270,000 | $22,262,000 | 4.27% |
| Ghost Tree Capital, LLC | 185,000 | $15,253,000 | 3.58% |